Current therapy and development of therapeutic agents for lung cancer
In the past decades, great progress has been made for the prevention and treatment of lung cancer. Yet, lung cancer remains as the leading cause of cancer death worldwide. In this manuscript, we describe the current genetic and molecular characterization of lung cancer subtypes, review up-to-date tr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Cell Insight |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772892722000128 |
| _version_ | 1798027000806375424 |
|---|---|
| author | Zilai Wang Jiyeon Kim Pin Zhang Jazmin M. Galvan Achi Yuwei Jiang Lijun Rong |
| author_facet | Zilai Wang Jiyeon Kim Pin Zhang Jazmin M. Galvan Achi Yuwei Jiang Lijun Rong |
| author_sort | Zilai Wang |
| collection | DOAJ |
| description | In the past decades, great progress has been made for the prevention and treatment of lung cancer. Yet, lung cancer remains as the leading cause of cancer death worldwide. In this manuscript, we describe the current genetic and molecular characterization of lung cancer subtypes, review up-to-date treatment options for lung cancer patients, summarize the antibodies and small molecule drugs under clinical development, and elaborate on the expression and characteristics of important RTK primary targets and representative preclinical agents which may provide new opportunities for lung cancer treatment. Since gefitinib was first introduced to non-small-cell lung carcinoma (NSCLC) patients in 2002, remarkable progress has been made in targeted therapy for NSCLC patients with the development of multiple generations of small molecule inhibitors targeting relevant driver mutations. However, very little achievement has been made in the development of targeted drugs for small-cell lung carcinoma (SCLC). The successful harness of immune checkpoint inhibitors against PD-1/PD-L1 has marked a major advancement in recent lung cancer treatment. Looking forward, therapeutic strategies that tackle brain metastasis are highly desirable, the combination of molecular testing and strategies tailored to tackle tumor heterogeneity and resistance mechanisms is the key direction for future development. |
| first_indexed | 2024-04-11T18:44:30Z |
| format | Article |
| id | doaj.art-b29e15c252c44f6885d20452acf2afbd |
| institution | Directory Open Access Journal |
| issn | 2772-8927 |
| language | English |
| last_indexed | 2024-04-11T18:44:30Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Insight |
| spelling | doaj.art-b29e15c252c44f6885d20452acf2afbd2022-12-22T04:08:53ZengElsevierCell Insight2772-89272022-04-0112100015Current therapy and development of therapeutic agents for lung cancerZilai Wang0Jiyeon Kim1Pin Zhang2Jazmin M. Galvan Achi3Yuwei Jiang4Lijun Rong5Chicago BioSolutions, Inc., 2242 W Harrison Street, Chicago, IL, 60612, USA; Corresponding author.Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, 60607, USAChicago BioSolutions, Inc., 2242 W Harrison Street, Chicago, IL, 60612, USADepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USADepartment of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USADepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA; Corresponding author. Department of Microbiology and Immunology, University of Illinois at Chicago, 8133 COMRB, 909 S. Wolcott Avenue, Chicago, IL, 60612, USA.In the past decades, great progress has been made for the prevention and treatment of lung cancer. Yet, lung cancer remains as the leading cause of cancer death worldwide. In this manuscript, we describe the current genetic and molecular characterization of lung cancer subtypes, review up-to-date treatment options for lung cancer patients, summarize the antibodies and small molecule drugs under clinical development, and elaborate on the expression and characteristics of important RTK primary targets and representative preclinical agents which may provide new opportunities for lung cancer treatment. Since gefitinib was first introduced to non-small-cell lung carcinoma (NSCLC) patients in 2002, remarkable progress has been made in targeted therapy for NSCLC patients with the development of multiple generations of small molecule inhibitors targeting relevant driver mutations. However, very little achievement has been made in the development of targeted drugs for small-cell lung carcinoma (SCLC). The successful harness of immune checkpoint inhibitors against PD-1/PD-L1 has marked a major advancement in recent lung cancer treatment. Looking forward, therapeutic strategies that tackle brain metastasis are highly desirable, the combination of molecular testing and strategies tailored to tackle tumor heterogeneity and resistance mechanisms is the key direction for future development.http://www.sciencedirect.com/science/article/pii/S2772892722000128BiomarkersImmunotherapyLung cancerNon-small cell lung carcinomaReceptor tyrosine kinasesReceptor tyrosine kinase inhibitors |
| spellingShingle | Zilai Wang Jiyeon Kim Pin Zhang Jazmin M. Galvan Achi Yuwei Jiang Lijun Rong Current therapy and development of therapeutic agents for lung cancer Cell Insight Biomarkers Immunotherapy Lung cancer Non-small cell lung carcinoma Receptor tyrosine kinases Receptor tyrosine kinase inhibitors |
| title | Current therapy and development of therapeutic agents for lung cancer |
| title_full | Current therapy and development of therapeutic agents for lung cancer |
| title_fullStr | Current therapy and development of therapeutic agents for lung cancer |
| title_full_unstemmed | Current therapy and development of therapeutic agents for lung cancer |
| title_short | Current therapy and development of therapeutic agents for lung cancer |
| title_sort | current therapy and development of therapeutic agents for lung cancer |
| topic | Biomarkers Immunotherapy Lung cancer Non-small cell lung carcinoma Receptor tyrosine kinases Receptor tyrosine kinase inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S2772892722000128 |
| work_keys_str_mv | AT zilaiwang currenttherapyanddevelopmentoftherapeuticagentsforlungcancer AT jiyeonkim currenttherapyanddevelopmentoftherapeuticagentsforlungcancer AT pinzhang currenttherapyanddevelopmentoftherapeuticagentsforlungcancer AT jazminmgalvanachi currenttherapyanddevelopmentoftherapeuticagentsforlungcancer AT yuweijiang currenttherapyanddevelopmentoftherapeuticagentsforlungcancer AT lijunrong currenttherapyanddevelopmentoftherapeuticagentsforlungcancer |